argenx announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.
argenx to Present at BofA Securities 2023 Health Care Conference Read More »
Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within Medigene’s end-to-end platform.
Biophytis SA announces the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance and the upcoming arrival of Nicolas Fellmann as Chief Financial Officer as of 22 May 2022.
Curasight A/S announced that it has entered into an exclusive global license and collaboration agreement with Curium Inc. – a global leader in radiopharmaceuticals – for the development and commercialization of uTRACE® for use in prostate cancer.
Curasight and Curium announce global partnership for uTRACE® in prostate cancer Read More »
Memo Therapeutics AG announced that the U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.
ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer Read More »
Hyloris Pharmaceuticals SA announces the US Food & Drug Administration has set 17 October 2023 as the date by which it expects to respond to the application regarding Maxigesic® IV.
Hyloris announces potential registration date for Maxigesic® IV in the US Read More »
Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that the US Food and Drug Administration has cleared its Investigational New Drug application for its second-generation DSR product for the treatment of congestive heart failure.
La American Heart Association califica qué tan cerca se alinean varios patrones de alimentación populares con la guía para una alimentación saludable para el corazón.
Medtronic received FDA approval for the first leadless pacemaker in 2016, but faces a new competitor in Abbott, which got the nod for its own leadless device last year.
Medtronic ramps up competition for leadless pacemakers with newly approved devices Read More »
